Clinical trials: Pancreatic Cancer Stage III
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer
Phase II trial to study the effectiveness of combining paclitaxel and bryostatin-1 in treating patients who have locally advanced unresectable or metastatic pancreatic cancer.
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT00031694
- Testing
- paclitaxel, bryostatin 1
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00057876
- Testing
- Gemcitabine, radiation therapy
- Where
- 229 sites in United States, South Africa
- Volunteers
- 74 people
- Sponsor
- Eastern Cooperative Oncology Group
Pancreatic Cancer
Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery
RATIONALE: Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00601627
- Testing
- panitumumab, capecitabine, fluorouracil
- Where
- 281 sites in United States
- Volunteers
- 52 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Estrogen Receptor-positive Breast Cancer, Gastrinoma
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
This phase II trial studies how well real-time pharmacokinetic therapeutic drug monitoring works in preventing stomatitis from developing in patients with hormone receptor positive breast cancer, pancreatic neuroendocrine tumors…
- Conditions
- Estrogen Receptor-positive Breast Cancer, Gastrinoma, Glucagonoma, HER2-negative Breast Cancer
- Trial name
- NCT02273752
- Testing
- Everolimus
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Emory University
Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma
Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery
This pilot clinical trial studies the side effects of ascorbic acid and combination chemotherapy in treating patients with pancreatic cancer that has spread to other places in the body, has come back, or cannot be removed by…
- Conditions
- Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT02896907
- Testing
- Oxaliplatin, Irinotecan Hydrochloride, Leucovorin Calcium
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Locally Advanced Unresectable Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer
This phase II trial studies how well telotristat ethyl works in promoting weight stability in patients with pancreatic adenocarcinoma that has come back and spread to other places in the body.
- Conditions
- Locally Advanced Unresectable Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
- Trial name
- NCT03910387
- Testing
- Gemcitabine, Nab-paclitaxel, Telotristat Ethyl
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Emory University
Primary Stage IV Hepatobiliary, Esophageal
Improving Goals of Care Discussion in Advanced Cancer Patients
The goal of this study is to increase and improve Goals of Care discussions for advanced cancer patients by training medical oncologists to conduct these discussions.
- Conditions
- Primary Stage IV Hepatobiliary, Esophageal, Colorectal Cancer, Glioblastoma
- Trial name
- NCT02374255
- Testing
- GoC intervention
- Where
- 4 sites in United States
- Volunteers
- 265 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Advanced Neuroendocrine Tumors of Pancreatic Origin
Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors
The purpose of this study was to evaluate progression free survival in those participants assigned everolimus 10 mg/day plus Best Supportive Care versus those assigned to placebo plus Best Supportive Care in Advanced…
- Trial name
- RADIANT-3 (NCT00510068)
- Testing
- Everolimus
- Where
- 82 sites in United States, Belgium and 16 more
- Volunteers
- 410 people
- Sponsor
- Novartis Pharmaceuticals
Adenocarcinoma of the Pancreas, Locally Advanced
Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas
This study is a phase 2, multicenter, randomized, double-blind, active placebo-controlled trial of AMG 479 or placebo in combination with gemcitabine as first-line therapy for locally advanced unresectable adenocarinoma of the…
- Conditions
- Adenocarcinoma of the Pancreas, Locally Advanced, Unresectable
- Trial name
- NCT01318642
- Testing
- Gemcitabine, AMG 479
- Where
- 35 sites in United States, Austria and 11 more
- Volunteers
- 10 people
- Sponsor
- NantBioScience, Inc.
Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer
This phase Ib trial studies the side effects and best dose of Hsp90 inhibitor XL888 when given together with pembrolizumab in treating patients with advanced gastrointestinal cancer that has spread to other places in the body.
- Conditions
- Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Colorectal Carcinoma, Recurrent Pancreatic Carcinoma
- Trial name
- NCT03095781
- Testing
- XL888, Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 47 people
- Sponsor
- Emory University
Pancreatic Adenocarcinoma, Poorly Differentiated Malignant Neoplasm
Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study
This phase II trial studies how well combination chemotherapy works in treating patients with pancreatic cancer before undergoing surgery.
- Conditions
- Pancreatic Adenocarcinoma, Poorly Differentiated Malignant Neoplasm, Resectable Pancreatic Cancer, Stage IA Pancreatic Cancer
- Trial name
- NCT02345460
- Testing
- Irinotecan Hydrochloride, Oxaliplatin, Leucovorin Calcium
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Case Comprehensive Cancer Center
Germline BRCA1/2 Mutations and, Metastatic Adenocarcinoma of the Pancreas
Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum…
- Trial name
- POLO (NCT02184195)
- Testing
- Olaparib
- Where
- 103 sites in United States, Australia and 10 more
- Volunteers
- 154 people
- Sponsor
- AstraZeneca
Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of ipilimumab when given together with gemcitabine hydrochloride in treating patients with stage III-IV or recurrent pancreatic cancer that cannot be removed by surgery.
- Conditions
- Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT01473940
- Testing
- ipilimumab, gemcitabine hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Northwestern University
Extrahepatic Bile Duct Cancer, Nausea
Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer
This pilot clinical trial is studying how well aprepitant works in preventing nausea and vomiting in patients undergoing chemotherapy and radiation therapy for pancreatic cancer.
- Conditions
- Extrahepatic Bile Duct Cancer, Nausea, Vomiting, Stage II Pancreatic Cancer
- Trial name
- NCT01534637
- Testing
- aprepitant, gemcitabine hydrochloride, capecitabine
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Wake Forest University Health Sciences
Cachexia
Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas
A safety \& efficacy clinical study of the investigational medicinal product BYM338 for the treatment of unintentional weight loss in patients with cancer of the lung or the pancreas
- Trial name
- NCT01433263
- Testing
- BYM338 active drug
- Where
- 10 sites in United States, Lithuania and 3 more
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Cancer
Gemcitabine and Oxaliplatin in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00536874
- Testing
- gemcitabine hydrochloride, oxaliplatin, protein expression analysis
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Pancreatic Carcinoma, Locally Advanced Pancreatic Carcinoma
Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study
This phase II trial studies how well ultrasound-guided verteporfin photodynamic therapy works for the treatment of patients with solid pancreatic tumors that cannot be removed by surgery (unresectable) or pancreatic cancer that…
- Conditions
- Advanced Pancreatic Carcinoma, Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Pancreatic Neoplasm
- Trial name
- NCT03033225
- Testing
- Endoscopic Ultrasound, Fluorescence Imaging, Photodynamic Therapy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Mayo Clinic
Pancreatic Adenocarcinoma, Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
This phase II trial evaluates whether early switching from modified fluorouracil/irinotecan/leucovorin/oxaliplatin (mFOLFIRINOX) chemotherapy regimen to a combination of gemcitabine and nab-paclitaxel (GA) before surgery is…
- Conditions
- Pancreatic Adenocarcinoma, Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8, Stage I Pancreatic Cancer American Joint Committee on Cancer v8, Stage III Pancreatic Cancer American Joint Committee on Cancer v8
- Trial name
- NCT04539808
- Testing
- Capecitabine, Fluorouracil, Irinotecan Hydrochloride
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- OHSU Knight Cancer Institute
Thromboembolism of Vein VTE in Colorectal Cancer, Thromboembolism of Vein in Pancreatic Cancer
Cancer Associated Thrombosis and Isoquercetin (CATIQ)
This research study is evaluating a drug called isoquercetin to prevent venous thrombosis (blood clots), in participants who have pancreas, non small cell lung cancer or colorectal cancer.
- Conditions
- Thromboembolism of Vein VTE in Colorectal Cancer, Thromboembolism of Vein in Pancreatic Cancer, Thromboembolism of Vein in Non-small Cell Lung Cancer
- Trial name
- CATIQ (NCT02195232)
- Testing
- Isoquercetin
- Where
- 11 sites in United States
- Volunteers
- 64 people
- Sponsor
- Jeffrey Zwicker, MD